Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intranasal esketamine for severe resistant major depression]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V]
2020	Ontario Health	5-Aminolevulinic Acid Hydrochloride (5 ALA)–Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with yellow fever vaccination
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intrathecal baclofen pump in spastic patients]
2020	Ontario Health	Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with oral cholera vaccination
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endometrial microbiome test in assisted reproduction]
2020	Ontario Health	Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eculizumab in the management of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Migalastat for Fabry disease]
2020	Agency for Healthcare Research and Quality (AHRQ)	Prevention, diagnosis, and management of opioids, opioid misuse, and opioid use disorder in older adults
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: safety of switching biologics and their interchangeability]
2020	Health Technology Wales (HTW)	The clinical effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis
2020	Agency for Care Effectiveness (ACE)	Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020	National Institute for Health and Care Excellence (NICE)	Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 617
2020	Agency for Care Effectiveness (ACE)	Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020	Agency for Healthcare Research and Quality (AHRQ)	Resource allocation and pandemic response: an evidence synthesis to inform decision making
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 618
2020	NIHR Health Technology Assessment programme	Basic versus biofeedback-mediated intensive pelvic floor muscle training for women with urinary incontinence: the OPAL RCT
2020	Agency for Care Effectiveness (ACE)	Epoprostenol for treating pulmonary arterial hypertension
2020	Agency for Healthcare Research and Quality (AHRQ)	Retention strategies for medications for addiction treatment in adults with opioid use disorder
2020	National Institute for Health and Care Excellence (NICE)	Sotagliflozin with insulin for treating type 1 diabetes. NICE technology appraisal guidance 622
2020	NIHR Health Technology Assessment programme	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study
2020	Agency for Care Effectiveness (ACE)	Vonoprazan for treating helicobacter pylori infection
2020	National Institute for Health and Care Excellence (NICE)	Patiromer for treating hyperkalaemia. NICE technology appraisal guidance 623
2020	Agency for Care Effectiveness (ACE)	Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020	National Institute for Health and Care Excellence (NICE)	Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 624
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2020	National Institute for Health and Care Excellence (NICE)	Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal). NICE technology appraisal guidance 625
2020	Agency for Care Effectiveness (ACE)	Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020	National Institute for Health and Care Excellence (NICE)	Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 626
2020	Agency for Care Effectiveness (ACE)	Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020	National Institute for Health and Care Excellence (NICE)	Lenalidomide with rituximab for previously treated follicular lymphoma. NICE technology appraisal guidance 627
2020	NIHR Health Technology Assessment programme	Dementia Care Mapping to reduce agitation in care home residents with dementia: the EPIC cluster RCT
2020	NIHR Health Services and Delivery Research programme	Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews
2020	Agency for Care Effectiveness (ACE)	Mycophenolate mofetil for immunosuppression
2020	Agency for Healthcare Research and Quality (AHRQ)	Strategies for patient, family, and caregiver engagement
2020	National Institute for Health and Care Excellence (NICE)	Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 628
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: update of the systematic review of the effects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus infections in children]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism
2020	Agency for Care Effectiveness (ACE)	Adalimumab for treating inflammatory conditions
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Paediatric cardiac surgery - literature review
2020	National Institute for Health and Care Excellence (NICE)	Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. NICE technology appraisal guidance 629
2020	NIHR Health Technology Assessment programme	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis
2020	Agency for Care Effectiveness (ACE)	Abiraterone for treating metastatic prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Larotrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 630
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections
2020	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment - extension of further conditions for nintedanib (Ofev®)
2020	National Institute for Health and Care Excellence (NICE)	Ustekinumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 633
2020	NIHR Health Technology Assessment programme	Stratified Care for Patients with Sciatica and Suspected Sciatica in Primary Care: a randomised trial (the SCOPiC trial - SCiatica Outcomes in Primary Care)
2020	NIHR Health Technology Assessment programme	Medically unexplained symptoms(MUS): primary care intervention
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
2020	National Institute for Health and Care Excellence (NICE)	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 634
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
2020	Agency for Healthcare Research and Quality (AHRQ)	Therapies for clinically localized prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 635
2020	NIHR Health Technology Assessment programme	A randomised parallel group double blind placebo-controlled dose ranging Trial of low dose adjunctive alTeplase during priMary PCI (T-TIME)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy
2020	National Institute for Health and Care Excellence (NICE)	Eculizumab for treating refractory myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 636
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: iStent® and iStent inject® trabecular bypass for micro-invasive glaucoma surgery (MIGS)]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis
2020	National Institute for Health and Care Excellence (NICE)	Ranibizumab for treating diabetic retinopathy (terminated appraisal). NICE technology appraisal guidance 637
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 638
2020	NIHR Health Technology Assessment programme	Pre-Operative Behavioural Intervention to Reduce Drinking before elective orthopaedic Surgery (Pre-Op BIRDS)
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: prevention of cardiovascular events and safety of SGLT2 inhibitors compared to DPP-4 inhibitors in a real-world setting in patients with type 2 diabetes]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. NICE technology appraisal guidance 639
2020	NIHR Health Technology Assessment programme	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
2020	NIHR Health Technology Assessment programme	Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Adverse effects of messenger RNA vaccines
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders, wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatment of depression in children and adolescents
2020	National Institute for Health and Care Excellence (NICE)	Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant. NICE technology appraisal guidance 640
2020	National Institute for Health and Care Excellence (NICE)	Testing strategies for Lynch syndrome in people with endometrial cancer. NICE diagnostics guidance 42
2020	NIHR Health Services and Delivery Research programme	Identifying appropriate symbol communication aids for children who are non-speaking: enhancing clinical decision making
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: evolving portrait of the use and clinical outcomes of transcatheter aortic valve implantation (TAVI) in Québec, an evaluation in the real-world context of care, 2013 to 2018]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic prophylaxis for lower extremity wound debridement in the outpatient setting
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Alpha-1-antitrypsin genotyping
2020	National Institute for Health and Care Excellence (NICE)	Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma. NICE technology appraisal guidance 641
2020	National Institute for Health and Care Excellence (NICE)	Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke. NICE diagnostics guidance 41
2020	NIHR Health Technology Assessment programme	Surgical fixation compared with cast immobilisation for adults with a bicortical fracture of the scaphoid waist: the SWIFFT RCT
2020	NIHR Health Technology Assessment programme	What is the effectiveness of varenicline compared with nicotine replacement therapy for long term smoking cessation and clinically important outcomes such as mortality, myocardial infarction and frequency of service use? Evidence from the Clinical Practice Research Datalink
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: RebinynTM (nonacog beta pegol) – coagulation factor IX (recombinant), notice of inclusion on the Liste des produits du système du sang du Québec]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Point of care vascular ultrasound
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	PSMA PET/CT imaging for informing treatment of patients with prostate cancer
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatments for acute pain: a systematic review
2020	National Institute for Health and Care Excellence (NICE)	Gilteritinib for treating relapsed or refractory acute myeloid leukaemia. NICE technology appraisal guidance 642
2020	National Institute for Health and Care Excellence (NICE)	High-sensitivity troponin tests for the early rule out of NSTEMI. NICE diagnostics guidance 40
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: recommendations concerning the information required to monitor nusinersen use in real-world settings]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Early mobilization to reduce medical inpatient length of stay and adverse